Soleno Therapeutics Files 8-K

Ticker: SLNO · Form: 8-K · Filed: 2025-08-18T00:00:00.000Z

Sentiment: neutral

Topics: regulatory-filing, 8-k

TL;DR

SOLENO filed an 8-K, standard compliance stuff.

AI Summary

On August 18, 2025, Soleno Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided excerpt.

Why It Matters

This filing indicates Soleno Therapeutics is complying with regulatory reporting requirements, which is standard practice for publicly traded companies.

Risk Assessment

Risk Level: low — The filing is a routine 8-K for regulatory compliance and does not appear to disclose any new material information or risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Soleno Therapeutics, Inc.?

The primary purpose of this 8-K filing is for Regulation FD Disclosure and to report Financial Statements and Exhibits.

What is Soleno Therapeutics, Inc.'s principal executive office address?

Soleno Therapeutics, Inc.'s principal executive office is located at 100 Marine Parkway, Suite 400, Redwood City, CA 94065.

What was Soleno Therapeutics, Inc.'s former company name?

Soleno Therapeutics, Inc.'s former company name was Capnia, Inc.

On what date was this 8-K report filed?

This 8-K report was filed on August 18, 2025.

What is the Standard Industrial Classification (SIC) code for Soleno Therapeutics, Inc.?

The Standard Industrial Classification (SIC) code for Soleno Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

From the Filing

0001193125-25-182184.txt : 20250818 0001193125-25-182184.hdr.sgml : 20250818 20250818065443 ACCESSION NUMBER: 0001193125-25-182184 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 34 CONFORMED PERIOD OF REPORT: 20250818 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250818 DATE AS OF CHANGE: 20250818 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SOLENO THERAPEUTICS INC CENTRAL INDEX KEY: 0001484565 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 770523891 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36593 FILM NUMBER: 251226249 BUSINESS ADDRESS: STREET 1: 100 MARINE PARKWAY, SUITE 400 CITY: REDWOOD CITY STATE: CA ZIP: 94065 BUSINESS PHONE: 650-213-8444 MAIL ADDRESS: STREET 1: 100 MARINE PARKWAY, SUITE 400 CITY: REDWOOD CITY STATE: CA ZIP: 94065 FORMER COMPANY: FORMER CONFORMED NAME: Capnia, Inc. DATE OF NAME CHANGE: 20100219 8-K 1 d69752d8k.htm 8-K 8-K SOLENO THERAPEUTICS INC false 0001484565 0001484565 2025-08-18 2025-08-18     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 18, 2025     SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)       Delaware   001-36593   77-0523891 (State or other jurisdiction of incorporation)   (Commission File No.)   (IRS Employer Identification Number) 100 Marine Parkway , Suite 400 Redwood City , CA 94065 (Address of principal executive offices) (650) 213-8444 (Registrant’s telephone number, including area code)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading symbols   Name of each exchange on which registered Common Stock, $0.001 par value   SLNO   NASDAQ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       ITEM 7.01 Regulation FD Disclosure During August 18-19, 2025, senior management of Soleno Therapeutics, Inc. (the “Company”) will participate in previously scheduled meetings with existing and potential investors as part of a non-deal roadshow hosted by Guggenheim Securities and Piper Sandler. A copy of the investor presentation to be used during these meetings is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (th

View on Read The Filing